Browse the evidence

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) significantly reduce energy intake and hunger while improving satiety, but current clinical trials largely fail to report detailed dietary quality or food intake data, limiting the ability to tailor nutritional counseling.

GLP-1 medications like semaglutide and tirzepatide effectively reduce hunger and energy intake, leading to significant weight loss. However, because most clinical trials do not report detailed dietary quality, patients should proactively track their food intake and nutrient quality to ensure long-term success and prevent nutritional deficiencies, as the drug alone does not guarantee healthy eating habits.

Short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate promote satiety and improve metabolic health by stimulating GLP-1 and PYY secretion and modulating gut-brain signaling, despite inconsistent fecal level measurements in obesity.

Consume fiber-rich foods to support SCFA production. This supports satiety hormones (GLP-1/PYY) and gut health, even if direct measurement of SCFAs is not feasible.

Elevated circulating branched-chain amino acids (BCAAs) and imidazole propionate (IMP) are causally linked to insulin resistance and type 2 diabetes, serving as predictive biomarkers years before clinical onset.

Monitor metabolic health through regular check-ups. Dietary patterns that improve insulin sensitivity (e.g., balanced macronutrients, fiber) can help manage BCAA and IMP levels.

Incretin-based medications (GLP-1 RAs, dual/tri-agonists) achieve high rates of glycemic control (HbA1c ≤ 6.5%) and weight loss, but technically do not constitute 'remission' as defined by the consensus (which requires being off medication), as the effect persists only while taking the drug.

Newer incretin-based medications (like GLP-1 and dual/tri-agonists) are highly effective at lowering blood sugar and promoting weight loss, with some trials showing over 80% of patients reaching normal HbA1c levels. However, this control is dependent on continuing the medication and does not constitute 'remission' in the strict sense of being off all drugs.

Discontinuation of incretin agonists (GLP-1/GIP) leads to significant weight regain (approx. two-thirds of lost weight) within weeks, indicating that current pharmacological efficacy is not sustainable without continuous treatment.

Current GLP-1 and GIP medications are not a one-time fix for obesity. If you stop taking them, you will likely regain most of the weight you lost. This suggests that obesity management with these drugs is a long-term commitment, similar to other chronic conditions, and requires ongoing medical supervision and cost consideration.

Once-daily oral semaglutide (up to 14 mg) reduces systolic blood pressure and total cholesterol in patients with type 2 diabetes.

If you have Type 2 Diabetes, adding oral semaglutide to your current regimen can help lower your systolic blood pressure and total cholesterol. The standard protocol starts at a low dose (3 mg) and increases to 14 mg daily over two months to minimize side effects. This oral option offers cardiovascular protection similar to the injectable version, which may be easier for you to stick with long-term.

Oral semaglutide consistently reduces LDL cholesterol and triglycerides, but its effect on HDL cholesterol is inconsistent and clinically insignificant.

Oral semaglutide helps lower 'bad' cholesterol (LDL) and triglycerides in most patients with Type 2 Diabetes. However, do not expect it to reliably raise 'good' cholesterol (HDL), as studies show mixed and clinically insignificant results for HDL changes.

GIP receptor (GIPR) antagonism enhances the weight-loss efficacy of GLP-1 receptor agonists by removing an inhibitory tone on central nervous system (CNS) satiety circuits, specifically within hindbrain GABAergic neurons.

If you are using a GLP-1 medication (like semaglutide or liraglutide) and experiencing significant side effects like nausea without sufficient weight loss, newer therapies that block the GIP receptor (antagonism) while activating GLP-1 may be more effective and tolerable. This works by removing a natural 'brake' on your brain's satiety signals, allowing the medication to work more efficiently.

GLP-1 receptor agonists (semaglutide and tirzepatide) produce highly heterogeneous weight loss outcomes, with 'super responders' achieving >15% body weight loss while 'minimal responders' achieve <5%, driven by distinct pre-treatment clinical phenotypes rather than uniform biological response.

If you are taking a GLP-1 medication like Ozempic or Mounjaro, understand that your weight loss outcome is not guaranteed to be 'super' (>15% loss). Your pre-existing health conditions (like sleep apnea, psoriasis, or fibromyalgia) may predict how well you respond. Focus on the health benefits of even moderate weight loss (5-15%) rather than comparing yourself to 'super responder' statistics, as individual biology plays a massive role in the final result.

Pre-treatment clinical phenotypes, specifically the presence or absence of certain comorbidities, are strongly associated with the likelihood of being a 'super responder' to specific GLP-1RA brands.

Your existing health conditions might predict how well a specific weight-loss drug will work for you. For example, those without fibromyalgia or osteoarthritis might respond better to Zepbound, while those with psoriasis might respond better to Wegovy. Discuss your full medical history with your provider to help select the most appropriate GLP-1RA.

Tirzepatide (Zepbound/Mounjaro) is associated with a higher proportion of 'super responders' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy) in real-world settings.

If you are choosing between GLP-1 medications, tirzepatide (Zepbound/Mounjaro) may offer a higher probability of 'super response' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy). However, individual response varies, and your specific health profile should guide the choice.

Dual-agonists targeting GLP-1 and Glucagon receptors (e.g., Mazdutide, Survodutide) offer superior weight loss and metabolic improvements compared to GLP-1 monotherapies, though they carry a higher risk of gastrointestinal adverse events.

Mazdutide is a once-weekly injection targeting both GLP-1 and Glucagon receptors. In trials, a 9mg dose led to an 18.6% average body weight loss over 48 weeks, outperforming many single-hormone drugs. However, patients should be aware of a higher rate of gastrointestinal side effects compared to some GLP-1 monotherapies, which may lead to discontinuation.

GLP-1 receptor agonists (GLP-1RAs) treat obesity by activating central and peripheral GLP-1 receptors to increase satiety, delay gastric emptying, and modulate energy expenditure, resulting in significant weight loss.

GLP-1 receptor agonists are a class of medications that mimic a gut hormone to signal fullness to the brain and slow digestion. They are prescribed for obesity and type 2 diabetes. Common examples include Semaglutide (Ozempic/Wegovy) and Liraglutide (Saxenda). These drugs require a prescription and often involve starting at a low dose to manage side effects like nausea. They are part of a long-term management strategy for obesity, not a quick fix.

GLP-1 receptor agonists (GLP-1 RAs) are displacing bariatric surgery as the primary obesity treatment in the US, evidenced by a 1451% increase in GLP-1 RA use and a 65% decline in bariatric surgery procedures.

GLP-1 medications are becoming the dominant obesity treatment in the US, largely replacing bariatric surgery in utilization trends. However, surgery remains a crucial option for severe obesity due to its durability, especially if GLP-1 medications are discontinued. Patients should discuss long-term adherence and potential side effects with their providers.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates rapidly increasing real-world utilization as both a glucose-lowering medication and an anti-obesity medication in patients with chronic kidney disease (CKD), with initiators showing high rates of obesity and morbid obesity.

For patients with CKD, tirzepatide is increasingly being used to manage both blood sugar and weight. Real-world data indicates that doctors are prescribing it more frequently, especially for those with obesity. While clinical trials have limited CKD representation, real-world usage is high and growing.

At higher doses (30% of energy), whey protein elicits a significantly greater insulinogenic response than soy protein, whereas at lower doses (15% of energy), both proteins produce similar insulin responses and have no differential effect on plasma glucose.

If you are healthy and normal weight, you can use either whey or soy protein for post-workout or meal supplementation without worrying about blood sugar spikes. At moderate amounts (around 15g protein), they behave the same. If you consume larger amounts (30g+), whey will trigger a higher insulin response than soy, but this did not negatively impact blood glucose levels in this study. For Asian Indians at higher risk for Type 2 Diabetes, moderate doses of either protein are equally effective for glucose homeostasis.

Carbohydrate-restricted diets facilitate greater fat loss and weight loss maintenance in individuals with high insulin secretion or insulin resistance compared to low-fat diets, primarily by reducing hunger and preserving energy expenditure.

If you struggle with weight loss despite eating less, you may have high insulin levels. Try reducing carbohydrates (especially refined grains and sugars) without strictly counting calories. This approach may help control hunger and preserve energy expenditure, making it easier to lose fat and keep it off, especially if you have insulin resistance or type 2 diabetes.

Dual GLP-1/GIP receptor agonism (e.g., tirzepatide) produces synergistic body weight loss compared to selective GLP-1 receptor agonists, a mechanism dependent on the interaction of signals in neurotensin-expressing neurons (Nts CeA) within the central amygdala.

Dual GLP-1/GIP medications (like tirzepatide) are more effective for weight loss than GLP-1-only drugs because they activate a specific brain pathway (neurotensin neurons in the central amygdala) that GLP-1 drugs alone do not fully engage. This biological synergy is the reason for their superior efficacy, not just better stomach tolerance.

Weekly subcutaneous semaglutide (2.4 mg) significantly improves functional capacity and reduces heart failure hospitalizations in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction (HFpEF) and obesity, ask your doctor about weekly semaglutide injections (2.4 mg). This treatment has been shown to significantly improve your ability to perform daily activities, reduce your body weight, and lower your risk of being hospitalized for heart failure.

Semaglutide 2.4 mg administered once weekly for 68 weeks significantly improves health-related quality of life (HRQoL) utility scores compared to placebo in adults with overweight or obesity.

If you are an adult with overweight or obesity, taking 2.4 mg of semaglutide once weekly for about 16 months, alongside diet and exercise changes, is likely to significantly improve your daily health quality of life compared to placebo. This benefit is particularly pronounced if you have a higher BMI (over 40) or specific conditions like knee osteoarthritis or sleep apnea.

GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) cause significant loss of lean muscle mass (up to 40% of total weight loss), which contributes to reduced resting energy expenditure and increased risk of sarcopenia and weight regain.

If you are taking GLP-1 drugs, expect to lose some muscle along with fat. To protect your metabolism and strength, you must prioritize resistance training and adequate protein intake during your weight loss journey.

The 'borderline stage' of obesity (BMI 28-31.9 kg/m²) is a critical transitional phase characterized by elevated triglycerides, insulin resistance, and low-grade chronic inflammation, representing a vital window for early intervention to prevent clinical obesity.

If your BMI is between 28 and 31.9, do not assume you are safe. Look for metabolic red flags: high triglycerides, insulin resistance, or low-grade inflammation. This is your window to intervene with lifestyle changes (diet, activity) before clinical obesity and its complications set in.

Discontinuation of semaglutide or tirzepatide after 3-12 months of treatment results in negligible average weight change (mean +0.5% for obesity indication, -1.3% for T2D) over the subsequent year, driven by high rates of medication reinitiation (19.6%) or switching to alternative treatments (35.2%).

If you stop semaglutide or tirzepatide, do not assume you will regain all your weight. In clinical practice, most patients either restart the medication or switch to another treatment, which keeps average weight change very small (near zero) over the next year. However, individual results vary widely, so you must actively engage with your healthcare provider to select a replacement strategy (medication or lifestyle) immediately upon discontinuation to avoid regain.

Tirzepatide (a dual GIP/GLP-1 agonist) is better tolerated regarding GI side effects compared to semaglutide (a GLP-1 agonist), likely due to GIP receptor activation having anti-emetic properties.

If you struggle with stomach issues on Semaglutide (Ozempic/Wegovy), ask your doctor about Tirzepatide (Mounjaro/Zepbound). Clinical trials show it causes fewer GI side effects and fewer people stop taking it, possibly because of how it interacts with GIP receptors in the gut.